Last reviewed · How we verify

sufentanil-ropivacaine combination

Peking University First Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

sufentanil-ropivacaine combination is a Small molecule drug developed by Peking University First Hospital. It is currently FDA-approved. Also known as: epidural analgesia using the sufentanil-ropivacaine combination.

Sufentanil-ropivacaine combination is a small molecule modality used in epidural labor analgesia, as studied in clinical trials such as NCT05698407. This combination is being investigated for its effects on neonatal outcomes, among other conditions, including pregnancy-related and postpartum depression.

At a glance

Generic namesufentanil-ropivacaine combination
Also known asepidural analgesia using the sufentanil-ropivacaine combination
SponsorPeking University First Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sufentanil-ropivacaine combination

What is sufentanil-ropivacaine combination?

sufentanil-ropivacaine combination is a Small molecule drug developed by Peking University First Hospital.

Who makes sufentanil-ropivacaine combination?

sufentanil-ropivacaine combination is developed and marketed by Peking University First Hospital (see full Peking University First Hospital pipeline at /company/peking-university-first-hospital).

Is sufentanil-ropivacaine combination also known as anything else?

sufentanil-ropivacaine combination is also known as epidural analgesia using the sufentanil-ropivacaine combination.

What development phase is sufentanil-ropivacaine combination in?

sufentanil-ropivacaine combination is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing